← AGACNP I Clinical Buddy Course study buddy →
Week 04 · September 14 · Directed Reading

Pulmonary Disorders I

The foundations week: how the lung is perfused, ventilated, and measured — then how it is imaged, tested, and machine-ventilated when it fails, and the obstructive diseases that slowly steal that function. Eight chapters, one page — everything below is drawn from your assigned reading.

8 chapters 99 pages Ch 22 · 23 · 24 · 25 · 35 · 30 · 26 · 27 Fully offline
Orientation

How to read this week

Week 4 is the whole lung in one pass: the physiology of oxygenation and ventilation, the tools that measure it, the chest X-ray and PFTs, the ventilator, respiratory failure — and the diseases themselves. The obstructive ones fail slowly (COPD, asthma, bronchiectasis); the restrictive and inflammatory ones scar and flood the lung (pneumonia, TB, ARDS, IPF, sarcoidosis, cardiogenic pulmonary edema).

Half one

Physiology & measurement

  • Perfusion, ventilation, diffusion
  • Oxygen transport & the dissociation curve
  • ABGs, pulse oximetry, capnometry
  • PA catheter & hemodynamics
  • Fluid resuscitation

Diagnostic currency: numbers — pH, PaO₂, PaCO₂, SvO₂, and the ratios built from them.

Half two

Imaging, the ventilator & disease

  • The chest X-ray (AP/PA, ABCDEHI)
  • Pulmonary function testing
  • Mechanical ventilation & weaning
  • Respiratory failure — Types 1–4
  • COPD, asthma, bronchiectasis
  • Pneumonia · TB · ARDS · IPF · sarcoidosis · cardiogenic pulmonary edema

Diagnostic currency: images, spirometry traces, ventilator settings, and FEV₁.

Your reading map

The eight chapters behind this week
Ch.TitleWhat it actually contains
22 Diagnostic Concepts of Oxygenation & Ventilation Perfusion · ventilation · alveolar diffusion & A-a gradient · oxygen transport · oxyhemoglobin dissociation curve · SvO₂ · ventilator adjustments for acid-base problems
23 Measures of Oxygenation & Ventilation ABGs · pulse oximetry · clinical perfusion (PA catheter) · capnometry · fluid resuscitation Normal ABG values, the SpO₂–PaO₂ pairs, and the crystalloid/colloid rules
24 The Chest X-ray AP/PA/lateral views · film adequacy · silhouette, interstitial & alveolar patterns · ABCDEHI search · invasive device positioning · specific disease entities
25 Pulmonary Function Testing Spirometry · bronchodilator response · plethysmography · DLCO · exhaled NO · bronchial provocation · peak flow zones · obstructive vs restrictive · severity grading
35 Mechanical Ventilatory Support Indications · general principles · variables & alarms · modes · airway management · suctioning · weaning & extubation
30 Respiratory Failure Breathing vs ventilation vs respiration · effects of aging · ventilatory failure · Types 1–4 · treatment
26 Obstructive (Ventilatory) Lung Diseases COPD · asthma · COPD/asthma dual diagnosis · bronchiectasis · obstructive airway lesions
27 Restrictive (Inflammatory) Lung Diseases & CHF/Pulmonary Edema Pneumonia · Tuberculosis · ARDS/ALI · Idiopathic pulmonary fibrosis · Sarcoidosis · Cardiogenic pulmonary edema
The organizing principle

Oxygenation is getting O₂ into blood; ventilation is moving CO₂ out; diffusion is the membrane between them; and delivery is what the circulation does with it all. When you understand which of those four has failed, the ABG, the chest X-ray, and the ventilator settings stop being a pile of numbers and start being a map.

The numbers worth carrying in

6 L/min
Pulmonary blood flow
A high-volume, low-resistance circuit with a mean pulmonary arterial pressure of only 15 mmHg.
35–45 mmHg
Normal PaCO₂
The single best indicator of alveolar ventilation — a rising PaCO₂ means ventilation is failing.
<70%
FEV₁/FVC = obstruction
The ratio of FEV₁ to FVC below 70% is diagnostic for obstructive lung disease.
45 cm H₂O
Peak-pressure barotrauma risk
Persistent breath-to-breath peak pressures greater than 45 cm H₂O are a risk factor for barotrauma.
Chapter 22

Oxygenation & Ventilation

Four separate jobs, four separate places to fail. Perfusion moves blood through the pulmonary capillaries; ventilation moves air into and out of the alveoli; diffusion exchanges gas across the alveolocapillary membrane; and transport carries O₂ on hemoglobin to tissue. Keep them separate in your head and they become separate in the patient.

Pulmonary perfusion

Blood flow through the lung

  • Movement of mixed venous blood through the pulmonary capillary bed for gas exchange with alveolar air
  • A high-volume, low-resistance system — pulmonary blood flow ≈ 6 L/min, mean pulmonary arterial pressure 15 mmHg
  • Lung bases receive a greater percentage of flow than the apices (blood must flow against gravity to the apices when upright)
Ventilation

Air movement into & out of alveoli

  • Mechanical movement of air for gas exchange between atmosphere and capillary blood; gas flows from higher atmospheric to lower intrapulmonary pressure on inhalation
  • Alveolar ventilation = air that reaches alveoli and participates in gas exchange
  • PaCO₂ is the best indicator of alveolar ventilation (normal 35–45 mmHg)

What shifts blood flow in the lung

Gravity

Hydrostatic pressure

Blood must flow against gravity to reach the apices in the upright position — so bases are better perfused than apices.

Alveolar pressure

When it exceeds capillary pressure

  • Positive pressure ventilation
  • Decreased RV preload — dehydration, hemorrhage
  • Air trapping in COPD
Hypoxic reflex

Decreased PaO₂

A local reflex that causes vasoconstriction of pulmonary arterioles supplying hypoxic alveoli.

Regulation of ventilation

Central control

Brain stem & cortex

  • Medulla and pons fire automatically — some cells trigger inhalation, others halt it; exhalation is passive
  • The cerebral cortex allows voluntary override in response to chemical stimuli and lung inflation changes
Chemical control

What the chemoreceptors sense

  • Central chemoreceptors (medulla) respond to ↑ PaCO₂ (hypercapnia) and ↓ pH (acidosis) by increasing depth and rate — hypercapnia is the major stimulus
  • Peripheral chemoreceptors (aortic and carotid bodies) respond to ↓ PaO₂ (hypoxemia)
The chronic-CO₂ patient

Patients with chronically high PaCO₂ lose the hypercapnic drive — they respond only to changes in PaO₂ (hypoxemic respiratory drive). Administer supplemental O₂ at low liter flows, very carefully (begin with 1–2 L/min and assess) to prevent apnea. Do not withhold O₂ if needed — be prepared to assist with mechanical ventilation if the drive is depressed.

Work of breathing, compliance & resistance

WOB

Work of breathing

Effort required to overcome the elastic and resistive properties of the lungs and chest wall.

Compliance

Distensibility

How easily lungs/thorax stretch. High compliance = easier to expand (COPD). Low compliance = stiff lungs (pneumonia, ARDS).

Resistance

Airway radius

Determined by airway radius — increased resistance = increased effort and increased WOB.

Alveolar diffusion & the A-a gradient

Diffusion is the exchange of O₂ and CO₂ across the alveolocapillary membrane — O₂ down its gradient from alveolar (PAO₂) to capillary (PaO₂). CO₂ diffuses across the membrane far more readily than O₂. The A-a gradient (AaDO₂) = PAO₂ − PaO₂, and it diagnoses the degree of hypoxemia.

The alveolar gas equation

PAO₂ = FiO₂ × (Pb − PH₂O) − (PaCO₂ ÷ 0.8)
FiO₂ = 21%–100% · Pb = barometric pressure 760 mmHg (sea level) · PH₂O = water vapor 47 mmHg · 0.8 = respiratory quotient.
On room air: 0.21 × (760 − 47) − (40 ÷ 0.8) = 0.21 × 713 − 50 = ≈ 100 mmHg.

<10 mmHg
A-a gradient — young adult
Normal alveolar–arterial difference breathing room air (FiO₂ 21%).
<20 mmHg
A-a gradient — over 60
The acceptable difference rises with age on room air.
<50 mmHg
A-a gradient on 100% O₂
The normal ceiling widens when breathing FiO₂ 1.0.

Oxygen transport in the circulation

3%

Dissolved in plasma

PaO₂ — normal 80–100 mmHg. A tiny reserve for times of increased demand.

97%

Bound to hemoglobin

SaO₂ (oxygen saturation) — normal 95%–100%. Assess the hemoglobin level: if Hgb is low yet adequately saturated, the patient is not adequately oxygenated.

Affinity is the whole game

O₂ that stays bound to hemoglobin is useless to body cells. Weak affinity releases O₂ to tissue easily; strong affinity accepts and retains it. The dissociation curve describes exactly where that balance sits.

The oxyhemoglobin dissociation curve

Flat where the lung loads, steep where the tissue unloads. Left shift holds on tighter; right shift lets go. Hover the curves.

100 75 50 0 SaO₂ (%) 20 40 60 80 100 PaO₂ (mmHg) PaO₂ 60 Normal curve — flat part (binding in the lungs): PaO₂ 60–100 mmHg with SaO₂ > 90%. Steep part (dissociation at tissue): PaO₂ below 60. Shift to the left — greater affinity: binds easily in the lung, unloads less to tissue (possible tissue hypoxia). Caused by alkalosis, hypothermia, decreased 2,3-DPG. Shift to the right — decreased affinity: unloads more O₂ to tissue, as long as loading in the lung is adequate. Caused by acidosis, increased metabolism / anaerobic metabolism / hyperthermia, increased 2,3-DPG. flat — lung loads here steep — tissue unloads here
Normal Left shift — ↑ affinity Right shift — ↓ affinity
Left shift

Greater affinity

Binds easily in the lung but unloads less to tissue — possible tissue hypoxia from the strong Hgb–O₂ bond.

  • Alkalosis
  • Hypothermia
  • Decreased 2,3-DPG
Right shift

Decreased affinity

Unloads more O₂ to tissue — delivery improves as long as loading in the lungs is adequate.

  • Acidosis
  • Increased tissue metabolism, anaerobic metabolism, hyperthermia
  • Increased 2,3-DPG

SvO₂ — mixed venous oxygen saturation

Monitored continuously through the PA catheter. Normal SvO₂ is 75% — hemoglobin unloads 25% of its oxygen before returning to the heart, and the normal supply-to-demand ratio is 4:1. Acceptable range 60%–80%.

Venous vs. arterial blood gases
ValueVenousArterial
pH7.367.40
PCO₂47 mmHg40 mmHg
HCO₃24 mEq/L24 mEq/L
PO₂40 mmHg100 mmHg
SO₂75%99%
Reading SvO₂ trends
  • SvO₂ < 60% (or trending down) — the venous reserve is tapped; greater risk of anaerobic metabolism. Causes: ↓ O₂ supply (↓ FiO₂, anemia, ↓ CO) or ↑ O₂ demand (fever, ↑ WOB, shivering, pain, agitation).
  • SvO₂ < 40% — anaerobic metabolism leading to organ dysfunction.
  • SvO₂ > 80% — decreased tissue extraction; an earlier indicator of change than hemodynamics. Causes: ↑ supply (FiO₂ > need, polycythemia), ↓ demand (sleep, hypothermia), or ↓ effective delivery/uptake (sepsis, cyanide toxicity, left-shifted curve).

Prolonged SvO₂ and/or prolonged VO₂ carry a poor prognosis.

Oxygen delivery, return & consumption

The supply–demand math

DO₂ (arterial delivery) = CI × (1.34 × Hgb × SaO₂) × 10 ≈ 600 mL/min/m²
VO₂ (consumption) = DO₂ − ROI₂ ≈ 600 − 450 = 150 mL/min/m²
where ROI₂ (venous return) = CI × (1.34 × Hgb × SvO₂) × 10.

Respiratory acidosis — the goal is to decrease PCO₂

  • Increase the respiratory rate (watch for auto-PEEP and hypotension from reduced preload at high rates)
  • Increase the tidal volume — in assist control, raise it directly; in pressure control / pressure support, raise inspiratory pressure
  • In acute lung injury, tolerate some hypercapnia rather than raising tidal volume > 8 ml/kg

Respiratory alkalosis — the goal is to decrease PCO₂

  • Decrease the respiratory rate; decrease the tidal volume (these won't work if the patient is breathing faster than the set rate)
  • Determine and correct the cause — sepsis, pulmonary embolism, pain, etc.

Hypoxemia — improve tissue oxygenation (SaO₂, PO₂, PaO₂)

  • Increase FiO₂; increase PEEP (watch the drop in cardiac output from decreased preload — augment preload with IV fluids)

Difficult ventilation first shows up as ↑ peak inspiratory pressure

  • Bronchospasm · secretions in airways/ETT/tubing · pulmonary edema · pneumothorax · right-mainstem intubation · mucus plug · worsening airspace disease (ARDS, pneumonia, edema) · agitated patient with ventilator dyssynchrony
Chapter 23

Measures of Oxygenation & Ventilation

Oxygenation is the movement of O₂ into blood and its delivery to tissue (via diffusion gradients, hemoglobin affinity, and perfusion). Ventilation is the exchange of extrapulmonary and intra-alveolar gas — resupplying O₂ and removing CO₂. This chapter is the toolbox for measuring both.

Clinical measurements before the lab

Exercise tolerance

A normal exercise load

Climbing a flight of stairs without stopping suggests adequate oxygenation and ventilation.

Dyspnea & WOB

Reported or visible distress

Does the patient report distress? Does the patient appear distressed?

Cyanosis (late)

Unsaturated hemoglobin

Dusky bluish tint from excess unsaturated Hgb. The more central, the more severe (face/chest > fingertips). No visible cyanosis does not ensure adequate oxygenation.

Arterial blood gases

Normal ABG values

One reference axis. Hover each bar for its range — then use the step-by-step accordion below to interpret a real gas.

0 25 50 75 mmHg · mEq/L · % PaO₂ 80–97 mmHg 80–97 PaO₂ PaCO₂ 35–45 mmHg 35–45 PaCO₂ HCO₃ 22–26 mEq/L 22–26 HCO₃ SaO₂ greater than 98% > 98 SaO₂ pH 7.35–7.45 · base excess −3 to +3 mEq/L
PaO₂ PaCO₂ HCO₃ SaO₂
  1. Check pH. Normal 7.35–7.45. Below = acidemia; above = alkalemia.
  2. Check PaCO₂ (ventilation). Normal 35–45 mmHg. Ventilation is reciprocally reflected by PaCO₂ — a rising PaCO₂ means ventilation has decreased (and vice versa).
  3. Check the metabolic side. HCO₃ 22–26 mEq/L; base excess −3 to +3 mEq/L.
  4. Apply the 0.08 rule. Every 10 mmHg shift in PaCO₂ should produce a reciprocal 0.08 shift in pH — so a PaCO₂ of 50 predicts a pH of 7.32. Any difference from that predicted shift must be attributed to a concurrent metabolic imbalance or compensation.
  5. Interpret PaO₂ against FiO₂. As a rule, PaO₂ should be 4–5 times the percentage of O₂ (room air 21% → normal PaO₂ 80–97 mmHg). The PaO₂/FiO₂ ratio describes the degree of gas-exchange impairment — normal 300–500; low = impaired exchange; below 200 = severe hypoxemia.

Partial pressures and saturation decline as altitude above sea level increases. Handle the sample carefully: it must be heparinized, free of air bubbles, chilled if delayed, and not accidentally venous.

Pulse oximetry — the SpO₂ ↔ PaO₂ pairs to memorize

The relationship is nonlinear. Hover each bar; these three pairs are worth committing to memory.

0 30 60 mmHg SpO₂ 90% represents a PaO₂ of 60 mmHg 60 SpO₂ 90% SpO₂ 75% represents a PaO₂ of 40 mmHg 40 SpO₂ 75% SpO₂ 50% represents a PaO₂ of 27 mmHg 27 SpO₂ 50%
What distorts the oximeter
  • Carbon monoxide — carboxyhemoglobin is misread as oxyhemoglobin → false elevation. Suspect CO poisoning? Use an ABG.
  • Methylene blue / methemoglobinemia — misread as deoxygenated hemoglobin → false low.
  • Alkalosis or hypothermia — PaO₂ may be lower than the SpO₂ predicts; acidosis or hyperthermia — PaO₂ may be higher.
  • Vasoconstriction (shock, hypothermia, severe PVD, high-dose vasopressors) — a peripheral probe won't reflect central oxygenation.
  • It measures saturation, not content. An anemic patient can be 100% saturated yet low in content — "100% of half is still half."
  • Pulse oximetry gives no information about pH, PaCO₂, or respiratory rate.

Measurement of clinical perfusion — the PA catheter

The device

Three lumina & a thermistor

  • Distal lumen opens at the tip (in the PA)
  • Proximal lumen opens ~30 cm from the tip (in the right atrium)
  • Balloon lumen inflates just proximal to the tip
  • ~100–110 cm long, markings every 10 cm; a temperature sensor at the tip permits thermodilution cardiac output
The readings

What each port tells you

  • CVP (proximal) = RV end-diastolic pressure (preload) → systemic volume status
  • PAP (distal, balloon down)
  • PCWP (distal, balloon wedged) = LV end-diastolic pressure (preload) → LV function
  • SvO₂ — less than 65% indicates systemic delivery is impaired

Placement

  • Introducer (6–8.5 French) at internal jugular, subclavian, or femoral site; catheter advanced by flow-directed balloon flotation; tip usually in the right PA branch
  • Inserted ≈ 50–60 cm for subclavian/IJ; 80–110 cm for femoral

Indications (only when less-invasive assessment is inadequate)

  • Differentiating cardiogenic (high PCWP, normal PAP) from pulmogenic (normal PCWP, high PAP) pulmonary edema
  • Direct measurement for titrating therapy — CO/CI, SVR, PVR, SvO₂

Relative contraindications

  • Coagulopathy · left bundle branch block · temporary pacing catheter · severe pulmonary hypertension (risk of PA rupture)

Complications

  • Sepsis — limit the site to 7–10 days
  • Pulmonary hemorrhage — minimal balloon inflation, wedge less than 10 seconds, never inflate against resistance; heralded by hematemesis
  • Dysrhythmias (ventricular stimulation, usually during placement)
  • Thrombocytopenia with prolonged placement

Capnometry: end-tidal CO₂ is 35–45 mmHg — 2–3 mmHg lower than PaCO₂ (difference > 3 mmHg when CO₂ production is elevated). Used to confirm ETT placement, track changes in cardiac output, detect overdistention, and monitor weaning.

The PaO₂/FiO₂ ratio

Normal is 300–500. Low ratios mean impaired O₂ exchange; below 200 is severe hypoxemia.

PaO₂/FiO₂ 300–500 — normal 300–500 PaO₂/FiO₂ low (below 300) — impaired oxygen exchange < 300 PaO₂/FiO₂ below 200 — severe hypoxemia < 200 Normal Impaired Severe 300 200 500 falling ratio →

Fluid resuscitation

Restoring cardiac output and organ perfusion by increasing intravascular volume — when there is no reason to suspect cardiogenic or neurogenic shock, and evidence of inadequate preload.

Inadequate volume

What signals it

  • Hypotension, tachycardia, low CVP, low PCWP
  • Flat neck veins in Trendelenburg
  • Urine output < 0.5 ml/kg/hr
  • History of volume wasting — hemorrhage, emesis/diarrhea, diaphoresis, excess diuresis, sepsis
Adequacy

How you know it worked

  • Normalization of BP and heart rate
  • Increasing urinary output
  • Normalization of CVP, PCWP, CO/CI, SVR
  • Resolution of lactic acidosis
Crystalloid

Normal saline & LR

0.9% NS is a good routine choice — but of 1 L given, only ~250 mL stays intravascular. High volumes → hyperchloremic acidosis. Lactated Ringer's is common in the OR. Dextrose solutions are not first-line for volume expansion.

Packed RBCs

Fluid of choice for hemorrhage

Each unit typically raises the hematocrit of a 70 kg person by 3%.

Colloid

Albumin — intravascular sponges

Oncotic attraction pulls volume intravascularly, but the effect is transient — reserve for specific indications such as refractory hypovolemia. FFP, platelets, and cryoprecipitate are not resuscitation fluids.

The logistics that matter
  • Manage serious resuscitation in a critical care setting with arterial line, CVP, and a urinary catheter
  • Warm fluids — cold fluids and blood products can chill the patient and, in bleeding patients, drive coagulopathy
  • Two large-bore IVs (16-gauge minimum), placed no more distal than the antecubital veins, may be lifesaving
Chapter 24

The Chest X-ray

Two views, one discipline: a systematic search pattern applied the same way every single time. The film tells you where and what kind of density change exists — it rarely names the disease by itself.

AP, PA & lateral — know what you're looking at

AP

Back against the plate

Portable, usually supine. More magnification, less sharpness. Supine limits inspiration and falsely widens the heart up to 15% and the mediastinum — and you can't assess free pleural fluid.

PA

Chest against the plate

X-ray suite, usually upright. Less magnification, sharper, deeper inspiration, dependent pleural fluid more evident, less cardiac distortion, scapulae lifted out.

Lateral

Left side against film

Best for the posterior mediastinal and retrocardiac spaces and thoracic vertebrae; may reveal free or loculated effusion not seen on supine AP.

Is the film even usable?

Penetration

Judged by vertebral bodies

  • Over-penetration — beam too intense, overly dark, subtle detail lost
  • Under-penetration — beam too weak, overly white, detail lost in glare
  • Air < fat < soft tissue/water < bone/metal absorb progressively more radiation
Rotation & inspiration

Two quick checks

  • Beam perpendicular, minimum 6 ft away; clavicles equal length and equidistant from the spinous process
  • Expose on deep inspiration — the 7th rib at or above the diaphragm is adequate; poor inspiration falsely widens the heart and crowds the hila

The two pattern languages

Silhouette & interstitial

Loss of borders & linear markings

  • Silhouette sign — loss of a normal border between densities (e.g., air-filled lung becomes water-dense), localizing the lesion: a density obscuring the right heart border sits in the right middle lung; one obscuring the hemidiaphragm sits in the right lower lung
  • Interstitial pattern — distinct linear/nodular markings as the interstitium gains water (IPF, radiation pneumonitis, scleroderma)
Alveolar

Consolidation & air bronchograms

  • Alveoli fill/consolidate/collapse — interstitial markings less distinct
  • Air bronchogram — air-filled bronchi in contrast against nonaerated lung
  • Usually acute; focal, multifocal, or diffuse (pulmonary edema, bronchopneumonia, hemorrhage, atelectasis)
  • Airway — trachea midline (displacement = thyroid enlargement or pressure shift); carina between T4–T6; right main bronchus is straighter, so aspiration consolidates the right middle/lower lobe
  • Bones — spine, clavicles, ribs (posterior ribs flatter; anterior sharper downward angle), scapulae; check each rib and intercostal width
  • Circulation / cardiac — widened mediastinum (heart failure, mass, lymphadenopathy, aneurysm/dissection); pneumomediastinum (trauma/esophageal injury); calcification = atherosclerosis; cardiothoracic ratio < 50%
  • Diaphragm — right is normally 1–3 cm higher than left (liver); 15% of people have a naturally higher left diaphragm; costophrenic angles sharp; air under the diaphragm = GI perforation (surgical emergency)
  • Edges — subcutaneous emphysema, pneumothorax, hemothorax, pleural effusions (175–250 mL to blunt a costophrenic angle)
  • Fields — review apices, hila, retrocardiac, and subdiaphragmatic zones (small lesions < 10 mm are often missed)
  • Gastric bubble — loss = hiatal hernia; large = bloating; air outside the GI tract = pneumoperitoneum
  • Hilum — overlap of pulmonary arteries/veins; left hilum usually 1–2 cm above the right; widening = pulmonary hypertension
  • Invasive lines — tubes, lines, drains, catheters, wires (Table 24.1)
Table 24.1 — Invasive devices & their correct position
DeviceProper location on the CXR
Endotracheal tube3–7 cm above the carina (or between T5–T7), not deviating to one bronchus
Chest tubeOpening inside the chest wall — tube travels up to drain air, down to drain fluid
Nasogastric / gastric tubeBelow the diaphragm, tip and side holes 10 cm into the antrum of the stomach, no loop back to the fundus
Post-pyloric feeding tubeTip into the duodenum, past the pylorus (confirm with abdominal film)
Central venous catheterTip in the superior vena cava, above the right atrium
Dialysis catheterTip ends in the superior vena cava
Pulmonary artery catheterAround the heart into the left or (more commonly) right pulmonary artery, 2–4 cm from midline, not in the periphery
PICCTip within the superior vena cava, above the right atrium
Intra-aortic balloon pumpTip in the aorta, 2 cm below the aortic arch
PacemakerLead touching the right atrium and right ventricle, along the lower right cardiac border
AICDLead in the SVC or brachiocephalic vein, and apex of the right ventricle

Specific disease entities on the film

Filter finding
Heart failure
Enlarged heart, flooded lung
  • Enlarged cardiac shadow with fullness of pulmonary vascular markings
  • Cephalization of pulmonary vasculature
  • Alveolar edema
  • Kerley B lines — horizontal lines < 2 cm, near the costophrenic angle
  • Pleural effusions often coexist
Emphysema
Lucency & hyperinflation
  • Parenchyma more lucent than normal (tissue loss + hyperinflation)
  • Narrow cardiac silhouette
  • Flattened diaphragmatic domes
  • Lung volumes appear larger
Pneumonia
Infiltrate in a segment

Suspected when an infiltrate is seen in a specific lung segment — but the diagnosis also requires clinical and laboratory findings. Radiographic improvement lags clinical improvement by weeks.

Nodules
Coin lesions
  • A nodule is < 3 cm; larger = a mass. Solitary nodules are always evaluated — compare with prior films first
  • Benign: nonsmokers < 35 yr, calcified (central, laminar, diffuse, popcorn), stable over time
  • Spiculated, eccentric, or stippled may be benign or malignant; CT and PET help
Pericardial effusion
Not a CXR diagnosis

The chest X-ray is not sensitive enough to detect it. Serial changes in size/hazy borders of the cardiac silhouette may suggest it — echocardiography is more reliable.

CT nodule follow-up & lung cancer screening

Solid nodules on CT

Fleischner-style follow-up

  • < 6 mm, low-risk adult — no follow-up imaging
  • 6–8 mm — follow-up CT in 6–12 months
  • > 8 mm — follow-up CT in 3 months
Lung cancer screening

Who gets yearly low-dose CT

  • Aged 55–80 years
  • Current smoker or quit within the past 15 years
  • 30 pack-years smoking history (packs/day × years)
  • Low-dose CT screening decreases mortality by 20%
Chapter 25

Pulmonary Function Testing

The PFT answers three questions: is there a defect, is it obstructive or restrictive, and does it reverse with a bronchodilator? It assigns a diagnosis, differentiates the two big defect classes, and trends response to treatment.

Obstructive defect

Can't get air out

  • Flow rates reduced compared with predicted
  • Lung volumes normal or larger — air trapping and hyperinflation (increased RV and TLC)
  • FEV₁/FVC < 70% (adults) = airflow obstruction
Restrictive defect

Can't get air in

  • Flow rates normal or increased
  • Lung volumes proportionately reduced — TLC is decreased
  • TLC normal or increased in obstructive disease

Obstructive vs. restrictive — the FEV₁/FVC pattern

FEV₁/FVC below 70% is the diagnostic ratio for obstruction. Hover each bar.

0 35 70 % Obstructive — FEV₁/FVC less than 70% of normal in adults; flow rates reduced, volumes normal or larger < 70 Obstructive Restrictive — FEV₁/FVC normal or increased; flow normal or increased, but volumes proportionately reduced normal–high Restrictive 70% line
Obstructive — flow ↓, volumes ↑ or normal Restrictive — flow normal, volumes ↓

The PFT menu

Filter test
Spirometry
FEV₁ & FVC — the cornerstone

FEV₁ is the gold standard for measuring obstructive airway disease; the FEV₁/FVC ratio is diagnostic for obstruction. Safe, inexpensive, fast — but effort dependent.

Positive bronchodilator response: an increase of 12% or 200 mL or more in FEV₁ (a smaller gain in the presence of more severe obstruction still argues for a trial).

Plethysmography
All lung volumes
  • Vital capacity, residual volume, and total lung capacity
  • Restrictive = lowered volumes; obstructive = increased TLC and RV
  • Interpret cautiously in neuromuscular weakness (can lower TLC and blur the distinction)
DLCO
Gas transfer (single-breath CO)
  • Decreased — parenchymal disorders, vascular problems, or loss of alveolar function (lung resection, emphysema)
  • Increased — asthma, obesity, polycythemia, cardiac left-to-right shunt
Exhaled NO
Airway inflammation marker

Elevated levels reflect airway inflammation — a hallmark of asthma. Useful for recognizing inflammation in symptom-free asthmatics with normal lung function, and for titrating inhaled steroids.

Provocation
Bronchial challenge

Inhaled methacholine/histamine to induce bronchoconstriction. Positive = FEV₁ fall of 20% or more at ≤ 16 mg/mL. 95% sensitive for asthma — a negative result makes asthma unlikely.

Max pressures
Neuromuscular function
  • ↓ inspiratory and expiratory pressures = generalized disease (e.g., ALS)
  • ↓ inspiratory = diaphragm dysfunction; ↓ expiratory = spinal cord injury
  • Guides airway-protective capacity, weaning, and progression
Peak flow
Home monitoring (not diagnosis)

Peak expiratory flow meters monitor asthma — they don't diagnose it. Record the "best" and daily values at the same time each day.

Peak expiratory flow — the three zones

Percent of the patient's baseline. Hover a zone for the action.

Green zone — PEFR 80–100% of baseline: no change in therapy needed 80–100% Yellow zone — PEFR 50–80% of baseline: consider a temporary increase in, or additional, therapy 50–80% Red zone — PEFR below 50% of baseline: urgent / emergency care is advised < 50% Green Yellow Red % of personal best
Green — no change Yellow — intensify Red — urgent care

Severity grading

Severity of defects (volumes & flow rates, % of predicted)
Value vs. predictedInterpretation
> 70%Within normal limits
60–70%Mildly reduced
50–60%Moderately reduced
< 50%Severely reduced
RV & TLC > 120%Air trapping and hyperinflation present
Bronchodilator responsiveness

With airflow obstruction present, a ≥ 15% improvement in expiratory airflow is significant — but the absence of a response is not, by itself, justification for withholding bronchodilators, which may improve secretion clearance and other parameters.

Geriatric PFTs
  • TLC usually remains relatively unchanged in the absence of disease
  • Tidal volume and vital capacity may decrease (chest wall stiffness); residual volume may increase, lowering vital capacity
  • Dyspnea is one of the primary reasons geriatric patients seek care — allow extra time for testing
Chapter 35

Mechanical Ventilatory Support

People suck to breathe; ventilators blow to breathe. Where normal inspiration lowers intrapulmonary pressure, the ventilator raises extrapulmonary pressure and forces air in — through a sealed airway, most often a cuffed endotracheal tube.

When to ventilate

Neuromuscular

Depression or failure

  • Drugs — opioids, sedatives, NM blockers
  • Trauma — spinal cord / phrenic nerve injury
  • Disease — Guillain-Barré, ALS, myasthenia gravis, shock
  • Exhaustion — status asthmaticus, sustained severe WOB
  • Sustained apnea of any cause
Persistent hypoxia/hypercarbia

Refractory to O₂ & airway care

PaO₂ < 60 mmHg and/or PaCO₂ > 50 mmHg refractory to supplemental O₂ and airway maintenance.

The defects

Diffusion · ventilation · perfusion

  • Diffusion — aspiration, pulmonary edema, ARDS, COPD, pneumonia
  • Ventilation — COPD, Pickwickian, flail chest, pneumothorax, atelectasis
  • Perfusion — shock, pulmonary embolus, malignant arrhythmias

Variables, settings & alarms

Core ventilator variables
VariableWhat to know
Tidal volume6–8 mL/kg ideal body weight in adults; keep plateau pressure ≤ 30 cm H₂O to prevent barotrauma; use the minimal effective tidal volume
RateMechanical breaths per minute; adjusted to meet pH and PaCO₂ goals
FiO₂Room air ≈ 0.21; ventilator settings typically 0.35–1. FiO₂ > 0.5 for more than 24 hr may cause oxygen toxicity
PEEPPrevents return of intrapulmonary to extrapulmonary pressure at end-expiration — incomplete expiration keeps more alveoli open (↑ PaO₂ without ↑ FiO₂, ↓ atelectasis). Typical 5–10 cm H₂O; "higher" PEEP up to 10–20 cm H₂O for low-compliance states (ARDS). Risks: barotrauma, ↓ venous return / cardiac output, ↑ ICP
CPAPFunctionally PEEP without mechanically delivered breaths (rate = 0); patient must have independent inspiratory capability
Pressure supportAugments flow during spontaneous inspiration to overcome circuit resistance and reduce WOB; at higher levels can provide full support

Written as mode/rate/tidal volume/PEEP/FiO₂ — e.g., AC 14/450/+5/.1 (100%).

Alarms — high pressure vs. low pressure

  • High-pressure (proximal airway pressure exceeds limit): secretions, coughing, spontaneous dyssynchrony, decreasing compliance, pneumothorax, airway occlusion
  • Low-pressure (pressure doesn't reflect function): disconnected tubing, ETT cuff leak
  • Low-volume (returned volume below set limit): disconnection, cuff leak, shallow spontaneous breaths
  • Low-FiO₂: interruption in oxygen supply · Apnea: no breath in the set window (patient apnea or mechanical failure)

The pressure thresholds that prevent injury

Peak and plateau pressure caps, plus the usual PEEP range — all in cm H₂O. Hover each bar.

0 20 40 cm H₂O PEEP — typical settings 5–10 cm H₂O (up to 10–20 cm H₂O for low-compliance states such as ARDS) 5–10 PEEP Plateau pressure — goal not to exceed 30 cm H₂O to prevent barotrauma 30 Plateau (≤) Peak pressure — persistent breath-to-breath pressures greater than 45 cm H₂O are a risk factor for barotrauma 45 Peak (risk)
PEEP Plateau ceiling Peak — barotrauma risk

The modes

Filter mode
CMV
Controlled mandatory ventilation

Set tidal volume at a set rate — no spontaneous breaths allowed. Sedation and/or NM blockade usually required to reduce anxiety and prevent interference.

Minute volume = set rate × set tidal volume.

AC
Assist control

Set tidal volume at a set rate, but the patient can trigger — receiving the set tidal volume with each spontaneous breath. Breaths are not synchronized; sedation may be needed to prevent hyperventilation and dyssynchrony.

Minute volume = (set rate + spontaneous rate) × set tidal volume.

IMVSIMV
Intermittent mandatory ventilation

Set tidal volume at a set rate, plus spontaneous breaths at the patient's own tidal volume. Delivery may be unsynchronized (IMV) or synchronized (SIMV). Typically used with pressure support.

Minute volume = (set rate × set TV) + (spontaneous rate × own TV).

PC
Pressure control

Set rate delivered up to a set pressure — tidal volume varies with compliance (low compliance → low TV → poor minute volume). May use inverse-ratio ventilation: lengthen inspiratory, shorten expiratory time → reduced barotrauma, improved oxygenation.

Airway & suctioning details that cost points
  • Humidify — a heat-moisture exchanger ("artificial nose") near the ETT, or a cascade "bubbler"
  • ETT cuff pressure — seal the airway without exceeding tracheal capillary filling pressure (~25–28 mmHg); keep cuff 2–4 mmHg below it, or use the minimal-leak technique
  • ETT position — tip not beyond the carina; 22-cm mark at the lips for most adults; 1–2 cm above the carina on CXR; bilateral breath sounds
  • Suction only as necessary — small catheter, moderate suction, oxygenate pre/peri/post; no more than three 10-second passes before resting; subglottal and in-line suction reduce pneumonia risk
  • Feed early and adequately — consider a small-bore tube beyond the pylorus

Weaning

The basic requirement: the original indication for ventilation has improved or been eliminated. Also consider time on the ventilator, psychological readiness, nutrition, cough, and hemodynamic stability.

Daily spontaneous breathing trial when

  • FiO₂ ≤ 0.40 and PEEP ≤ 8
  • PEEP and FiO₂ ≤ the previous day's values
  • Acceptable spontaneous efforts (may decrease vent rate 50% for 5 minutes to detect effort)
  • Systolic BP ≥ 90 mmHg without vasopressors
  • No NM blockade

Additional readiness criteria

  • Physical ability: RR < 30/min · minute ventilation < 12 L/min
  • Mechanical efficiency: vital capacity 10–15 mL/kg · negative inspiratory force > 20 cm H₂O
  • Oxygenation/ventilation: PaO₂ > 60 on FiO₂ < 0.50 · PaCO₂ < 50 with pH 7.35–7.45 · PEEP +5 or less with SaO₂ > 92%
  • Hemodynamics: cardiac index > 2.3 L/min/m² · heart rate 60–120 bpm · PCWP < 18 mmHg
  • Secretions: not copious, easily coughed to the ETT tip for suction

Technique

  • Spontaneous breathing trial for 30–120 minutes — if tolerated, the patient usually tolerates extubation; if not, delay to the next day and repeat daily
  • Alternate ventilator and CPAP to condition respiratory muscles; use pressure support to minimize ventilator-induced WOB
  • Extubate early in the day, with the patient rested, aware, and cooperative; have suction, O₂, and reintubation equipment ready
Chapter 30

Respiratory Failure

Keep three words straight: breathing is the act (intercostals + diaphragm), ventilation is the air movement (tidal volume × rate), and respiration is the cellular business — using O₂ for ATP and clearing CO₂ and hydrogen ions. Failure can happen at any one of those layers.

Ventilatory failure

Air can't move

Absent or inadequate movement of O₂ in and CO₂ out. Apnea = absence of gas movement; hypopnea = inadequate movement.

Best assessed by PaCO₂ and/or end-tidal CO₂ — a rising PaCO₂ means ventilatory failure.

Respiratory failure

Types 1–4

Classified by the mechanism that fails — hypoxemia (Type 1), hypercapnia (Type 2), atelectasis from low FRC (Type 3), or hypoperfusion of respiratory muscles (Type 4).

The four types

Filter type
Type 1Hypoxemia
PaO₂ < 60 mmHg
  • Impaired diffusion — pulmonary edema, pneumonia, pulmonary embolism
  • V/Q mismatching — atelectasis, airway obstruction, pneumonia
  • Right-to-left shunt — blood bypasses oxygenation (intracardiac or intrapulmonary, or PE) → mixed venous blood circulates
  • Low barometric pressure — high altitude
Type 2Hypercapnia
PCO₂ > 50 mmHg

In the absence of chronic CO₂ retention — falls in minute ventilation and alveolar hypoventilation.

  • Exacerbation of an underlying chronic condition
  • Airway obstruction (choking)
  • Neuromuscular disease · central respiratory failure
  • Increased dead space — emphysema
Type 3Atelectasis
Low functional residual capacity
  • General anesthesia
  • Upper abdominal surgery
  • Obesity
  • Smoking
  • Excessive airway secretions
Type 4Hypoperfusion
Respiratory muscles underperfused
  • Cardiogenic shock
  • Septic shock
  • Hypovolemic shock

Ventilatory failure — the causes

Overdose

Sedatives, hypnotics, opioids

Medication dose exceeds the body's ability to respond to metabolic and cellular needs. Elderly persons are particularly susceptible. Unintentional (iatrogenic over-sedation, especially in COPD) or intentional.

Acquired pathology

What impairs gas movement

  • Lung infections
  • Neuromuscular disease — myasthenic crisis, Guillain-Barré, ALS, head/spinal cord injury
  • Pulmonary edema (cardiogenic or noncardiogenic)
  • Musculoskeletal derangements — kyphosis
  • Conditions limiting thoracic expansion — hiatal hernia, cirrhosis with ascites
Effects of aging on the need for respiratory support
  • Physiologic: ↓ lung elasticity + ↑ V/Q mismatch · ↓ chest wall compliance and diaphragm/intercostal strength · ↓ secretion clearance · altered responsiveness to hypoxemia/hypercapnia
  • Comorbidities that raise the risk: heart failure, COPD, dementia, chronic inactivity, chronic kidney disease
  • Ethics: assess prior autonomous choices about life-prolonging interventions; family is crucial. Age alone is not an indication to withhold ventilator assistance.

Treatment

The goal

Prevent cellular ischemia and death while the cause is corrected — patent airway, adequate ventilation and oxygenation, and prevention of the problems mechanical ventilation itself causes (pneumothorax, barotrauma, volutrauma, oxygen toxicity, nosocomial pneumonia, catheter sepsis, malnutrition).

Hypoxemia alone

Unlabored, sustainable ventilation

Supplemental oxygen via mask or nasal cannula.

Hypoxemia + hypercapnia

Alert, increased WOB

  • Humidified high-flow O₂ (Vapotherm, Optiflow)
  • CPAP — for hypoxemia alone (e.g., CHF exacerbation)
  • BiPAP — for hypoxemia with hypercapnia (e.g., COPD exacerbation)
Somnolent / decreased ventilation

Intubate

Conventional mechanical ventilation; nonconventional modes (pressure control, APRV, HFOV) or strategies (partial liquid ventilation, ECMO) as needed.

Type 3 & Type 4 — the specifics
  • Type 3 (low FRC): elevate head of bed + frequent position changes · chest physiotherapy · control surgical-site pain · noninvasive positive pressure ventilation
  • Type 4 (muscle hypoperfusion): intubation and mechanical ventilation
  • Continue support for comorbid illness; start nutritional support as soon as possible during a time of higher caloric need
Chapter 26

Obstructive (Ventilatory) Lung Diseases

Airflow limitation is the shared signature. COPD is the slow, mostly irreversible loss; asthma is the variable, often reversible narrowing; bronchiectasis is the scarred, dilated airway that fills with sputum. The diagnosis lives in spirometry — the FEV₁/FVC ratio below 70% — and the treatment lives in inhaled bronchodilators.

COPD — definition & the three subtypes

Chronic bronchitis

Chronic productive cough

A chronic productive cough for 3 months, lasting into successive years, in the absence of other illness.

Emphysema

Structural change

Abnormal, permanent airspace enlargement distal to the terminal bronchioles with destruction of airspace walls, without overt fibrosis.

Bronchospastic

Asthma & reactive airway

Chronic inflammation with variable, often reversible airflow obstruction. The asthma/COPD overlap has features of both.

Etiology

Smoke is the disease engine
  • Tobacco smoking is the most common cause — most people smoking a pack/day for > 40 years will have manifestations; pack-years = packs/day × years. The single most important variable predicting airflow obstruction on spirometry is smoking history
  • E-cigarette users are twice as likely to have COPD
  • Environmental pollutants (oxides of sulfur/nitrogen) and occupational chemicals (chlorine, fluorine, toluene)
  • Rarely, alpha-1 antitrypsin deficiency — low AAT protein permits lung damage, and worsens fast with smoking

Clinical picture

Subjective

Three cardinal symptoms

  • Dyspnea with exertion, chronic cough, sputum production — cough starts in the early morning, then all day
  • Sputum usually clear; a change in amount or color matters (management decision)
  • Fatigue, chest tightness; weight loss (pulmonary cachexia) = worse prognosis
Objective

What you find

  • Tripod stance (leaning forward, arms braced) = end-stage; pursed-lip breathing
  • Barrel chest (↑ AP diameter; normally axilla-to-axilla ≈ 2× AP)
  • Accessory muscles (SCM, intercostals, scalenes); hyperresonance; low-set diaphragm (11th–12th posterior rib)
  • Diminished breath sounds; prolonged forced expiratory time (> 3 s); rhonchi; occasional expiratory wheeze
  • Clubbing suggests ILD, bronchiectasis, or lung cancer — not COPD

Diagnostics

Spirometry — cornerstone

FEV₁/FVC < 70 = obstruction

  • FEV₁ 80–100% mild · 50–80% moderate · 30–50% severe · < 30% very severe
  • Air trapping = ↑ RV; ↑ TLC/FRC/RV = hyperinflation; FVC may be reduced by trapping
ABG, oximetry & labs

Later & during exacerbations

  • Hypoxemia (PaO₂ < 55 mmHg) and hypercarbia (chronic respiratory acidosis) — seen later or in moderate-severe exacerbations
  • Oxygenation adequate if SaO₂ > 88% and Hgb > 10 g/dL
  • Hct > 55% = secondary polycythemia; serum bicarbonate rises with chronic hypercarbia
  • CXR: hyperlucency, flattened diaphragm, ≥ 10 ribs above the diaphragm, blebs/bullae

GOLD spirometric grades (postbronchodilator FEV₁)

Four categories of airflow-obstruction severity. Hover each grade.

30 80 % FEV₁ GOLD 1 — mild: FEV₁ 80% or greater of predicted ≥ 80 GOLD 1 GOLD 2 — moderate: FEV₁ 50% to less than 80% of predicted 50–80 GOLD 2 GOLD 3 — severe: FEV₁ 30% to less than 50% of predicted 30–50 GOLD 3 GOLD 4 — very severe: FEV₁ less than 30% of predicted < 30 GOLD 4
Mild Moderate Severe Very severe
A–D
GOLD groups (symptoms + risk)
A: low risk/few symptoms · B: low risk/more symptoms · C: high risk/few symptoms · D: high risk/more symptoms. Treatment follows the group, not the FEV₁ number.
<60%
FEV₁ that needs ICS
Below 60% predicted, inhaled corticosteroids improve symptoms, lung function, quality of life, and reduce exacerbations.
>88%
SaO₂ that implies adequacy
Adequate oxygenation when SaO₂ > 88% and hemoglobin is above 10 g/dL.
2×/yr
Exacerbations = deteriorating
Two or more exacerbations per year suggest declining lung function — a higher GOLD category.

COPD drug classes

Filter class
AntimuscarinicMainstay
Anticholinergics — agents of choice
  • Ipratropium (Atrovent) — 2 puffs 4×/day (SAMA)
  • Tiotropium (Spiriva) — 18 mcg once daily HandiHaler (LAMA)
  • Aclidinium (Tudorza) — 400 mcg inhaled BID
  • Umeclidinium (Incruse Ellipta) — 62.5 mcg inhaled daily

Adverse effects: dry mouth, dry hacking cough, oral candidiasis (rinse after use), urinary retention in elderly males with prostatic hypertrophy.

SABARescue
Short-acting β₂ agonists
  • Albuterol (Proventil, Ventolin)
  • Levalbuterol (Xopenex) — possibly less tachycardia/tremor than albuterol

Used for episodic symptom exacerbations; relax smooth muscle and stimulate ciliary motion.

LABAMaintenance only
Long-acting β₂ agonists
  • Salmeterol (Serevent) — up to 12 hr; Advair = salmeterol 50 + fluticasone 100/250/500, 1 puff BID
  • Formoterol (Foradil) — Symbicort = formoterol 4.5 + budesonide 80/160, 2 puffs BID (max); Dulera = formoterol 5 + mometasone 100, 2 puffs BID

Not recommended without a concomitant ICS (GOLD). Breo Ellipta (vilanterol 25/fluticasone 100, 1 puff daily) and Anoro Ellipta (vilanterol 25/umeclidinium 62.5, 1 inhalation daily) are not for asthma.

ICS
Inhaled corticosteroids
  • Reduce acute and chronic inflammation; long-term monotherapy no longer recommended — use with a LABA when exacerbations persist on bronchodilators
  • FEV₁ < 60% → ICS; blood eosinophils predict the magnitude of benefit
  • Examples: beclomethasone, budesonide, ciclesonide, flunisolide, fluticasone, mometasone
  • Relieve emphysema symptoms but do not improve FEV₁
PDE-4
Roflumilast (Daliresp)

500 mcg daily, later stages of disease — raises intracellular cAMP, reduces neutrophil/eosinophil counts in the lung.

Methylxanthine
Theophylline
  • Theo-Dur 300 mg BID · Uni-Dur 400–600 mg evening · Uniphyl 400–600 mg evening
  • Keep levels below 10–20 mg/L; evening doses acknowledge the circadian rise in airway tone
  • Only if other long-acting bronchodilators are unavailable/unaffordable
Mucolytics
Guaifenesin & acetylcysteine

Guaifenesin thins secretions (combine with hydration). Acetylcysteine (Mucomyst 10%/20%) — 1–10 mL nebulized q6h (usually after a β₂ agonist); can provoke bronchospasm.

COPD vs. asthma

COPD

Slow, mostly fixed

  • Smoking-driven, progressive; FEV₁/FVC < 70%, not fully reversible
  • Mainstay = anticholinergics (SAMA/LAMA) + LABAs; ICS only when FEV₁ < 60% or frequent exacerbations
  • Treatment cannot restore function — it prevents symptoms; the only thing that halts decline is removing toxins
  • Exacerbations: most common cause is bronchial infection → steroids + antibiotics ± BiPAP
Asthma

Variable, often reversible

  • Episodic, triggered (exercise, infection, allergens); often childhood onset, family history
  • Reversible obstruction demonstrated on spirometry; peak flow monitors but does not diagnose
  • Stepwise ICS-based control; SABA PRN at every step; step down after ≥ 3 months of good control
  • Inflammatory: bronchial smooth-muscle/mucous-gland hypertrophy, hyperreactivity, bronchospasm + mucus + edema
Steps & their preferred therapy
StepPatternPreferred management
Step 1 · Intermittent≤ 2 days/wk symptoms, ≤ 2 night awakenings/mo, FEV₁ > 80%SABA PRN — albuterol 2 inhalations q4h PRN; levalbuterol 2 inhalations q4–6h PRN; pirbuterol 2 inhalations q4–6h PRN
Step 2 · Mild persistent> 2 days/wk, 3–4 night awakenings/mo, FEV₁ > 80%Low-dose ICS — budesonide 180–360 mcg BID; ciclesonide 80 mcg BID; fluticasone 88 mcg BID; mometasone 220 mcg daily/BID. Alternative: leukotriene modifier (montelukast 10 mg daily; zafirlukast 20 mg BID; zileuton 600 mg QID or 1,200 mg BID)
Step 3 · Moderate persistentDaily symptoms, nightly awakening > 1×/wk, FEV₁ 60–80%Low-dose ICS + LABA or medium-dose ICS — Advair 100 mcg, 1 inhalation BID; Symbicort 80 mcg, 2 inhalations BID; Dulera 2 inhalations BID
Step 4 · Severe persistentThroughout the day, FEV₁ < 60%Medium-dose ICS + LABA — Advair 250 mcg, 1 inhalation BID; Symbicort 160 mcg, 2 inhalations BID
Step 5 · Severe persistent—High-dose ICS + LABA (Advair 500) ± biologics — omalizumab; benralizumab 30 mg subQ q4wk ×3 then q8wk; dupilumab 400 mg then 200 mg subQ q2wk; mepolizumab 100 mg subQ q4wk; reslizumab 3 mg/kg IV q4wk
Step 6 · Severe persistent—High-dose ICS + LABA + oral corticosteroid; consider hospitalization; consult specialist

Reevaluate control and adjust in 2–6 weeks. Step down if well controlled for ≥ 3 months. In the elderly, if reversibility hasn't been tested, consider 3 weeks of oral prednisone 20 mg daily then repeat spirometry.

COPD & asthma dual diagnosis (ACOS)

Treat the dominant phenotype

Asthma–COPD overlap syndrome has no standardized diagnostic criteria or directed management pathway. GINA and GOLD recommend treating according to the dominant phenotype. Over 40% of COPD patients self-report a history of asthma, and the dual diagnosis progresses more rapidly with more comorbidity and healthcare use. Highest risk: earlier-life onset, African Americans, females, less tobacco, and higher exacerbation rates.

Bronchiectasis & obstructive airway lesions

Bronchiectasis

Copious sputum

  • Periodic cough with copious sputum — one or more cups/day, occasionally bloody
  • Often postinflammatory — after severe pneumonia, bronchial obstruction by a foreign body, or healed TB
  • Exam: inspiratory rhonchi during exacerbations, noisy expiration
  • CXR may show fibrosis; CT documents airway dilatation and bronchial wall thickening
  • Manage with percussive therapy + postural drainage (flutter valve, percussive nebulizers, The Vest, PEP devices), generous mucolytics, and antibiotics — even prophylactically
Obstructive airway lesions

Endobronchial tumors & foreign bodies

  • Seen on CXR or suspected because of atelectasis; cough, dyspnea, hemoptysis, weight loss
  • CT shows a solid mass or irregularly shaped cavity in one lung; CXR shows a mass; fiberoptic bronchoscopy with biopsy; PET to find metastasis
  • Treatment follows the pathology — surgery, chemotherapy, radiation, or a combination
COPD — the realities
  • No treatment restores lung function; removing toxins is the only way to prevent further deterioration
  • Exacerbations: mild = SABA only · moderate = SABA + antibiotics and/or oral corticosteroids · severe = hospitalization or ER (may progress to acute respiratory failure)
  • Systemic steroids (prednisone 40 mg/day with breakfast × 5–7 days; methylprednisolone 64 mg/day tapered; Solu-Medrol 20–40 mg IV q6–8h) — taper rapidly; caution in the elderly
  • Lung transplantation and lung volume reduction surgery are the surgical options; offer palliative care for severe/advanced disease
Chapter 27

Pneumonia

An acute febrile inflammatory disorder of the lung(s) — a lower respiratory tract infection with an infiltrate on chest X-ray. The infiltrate may lag behind the symptoms by 24–48 hours, which is why a repeat film at that point is justified.

Definition

What makes the diagnosis

  • Cough, exertional dyspnea, fever
  • Leukocytosis may be present
  • Radiographic infiltrate — required

May be bacterial, viral, fungal, or parasitic.

Risk

Who gets into trouble

  • Age > 65
  • Chronic comorbidities · viral respiratory infection
  • Impaired airway protection · smoking
  • Recent antibiotic use
  • Immunocompromised — HIV, chemotherapy, transplant
Comorbidity

What drives mortality

  • Congestive heart failure
  • Diabetes mellitus
  • Chronic liver and renal disease
  • COPD

The very young and the very old die disproportionately.

Typical vs. atypical

Typical

Classic findings

  • Fever
  • Chills
  • Leukocytosis
  • Cough, with or without sputum
  • Sputum production
  • Increased fremitus
Atypical

Variable presentation

  • Fever may be high
  • Leukocytosis may be absent — or a left shift with "band" forms
  • Cough often dry
  • Headache, sore throat, excessive sweating, chest soreness
  • More often diffuse; may involve more than one segment or both lungs

Both forms demonstrate an infiltrate on chest X-ray. Time of year, known epidemics, and comorbid conditions help define which type you're facing.

The three clinical categories

CAP

Community-acquired

Acquired in the community setting — or within 48 hours of hospital admission.

Most common organism: S. pneumoniae — the most common bacterial cause in adults.

HAP

Hospital-acquired

Occurs 48 hours or more after admission, not incubating at admission. Includes VAP and healthcare-associated pneumonia.

Most common: S. aureus, S. pneumoniae, H. influenzae.

VAP

Ventilator-acquired

Arises more than 48–72 hours after endotracheal intubation.

Most common organism: Pseudomonas.

Also categorize by mechanism
  • Aspiration — altered mental status or dysphagia from stroke or neuromuscular disease (e.g., Parkinson disease)
  • Obstructive lesions — tumor, retained bronchopulmonary secretions
  • Inhalation injury — hypersensitivity pneumonia, near drowning

Who causes community-acquired pneumonia

Filter class
Bacterial
Classic pyogenic organisms
  • Streptococcus pneumoniae — most common bacterial cause in adult CAP
  • Klebsiella pneumoniae
  • Haemophilus influenzae
  • Gram-negative organisms
Atypical
The "walking" pathogens
  • Chlamydia pneumoniae
  • Mycoplasma pneumoniae
  • Mycobacterium tuberculosis
  • Legionella
Viral
Respiratory viruses
  • Respiratory syncytial virus
  • Adenovirus · rhinovirus
  • Influenza A or B
  • Parainfluenza

Evaluation

Highest sensitivity — rules out when absent

  • Fever > 38 °C with chills/shivering
  • Pleuritic chest pain
  • Cough productive of mucopurulent sputum
  • Dyspnea
  • Tachypnea — especially over age 65

Highest specificity — rules in when present

  • Asymmetric breath sounds
  • Pleural rubs
  • Egophony
  • Increased tactile fremitus
The diagnostic workup
  • CBC with differential WBC count
  • Blood cultures
  • Gram stain and culture of sputum
  • ABGs and/or pulse oximetry
  • Procalcitonin, when available — may aid diagnosis of bacterial pneumonia and guide duration of therapy
  • Chest X-ray — searching for a new infiltrate

On exam, look for tachypnea, tachycardia, fever, discomfort, rales ("crackles") over the affected area, and mental status changes or confusion.

Treatment principles

  • Start empiric antimicrobial therapy with cultures pending.
  • Revise as culture data returns and the patient improves — use the narrowest-spectrum agent to which the known organism is expected to respond.
  • Cover anaerobes in known or suspected aspiration.
  • Treat coexisting illness simultaneously — COPD, CHF, diabetes, dehydration.
  • Not everyone needs admission. Young adults in particular may be managed as outpatients.
The hospitalization decision

Guided by three things:

  • The possibility of rapidly progressive disease
  • The patient's overall status and coexisting problems
  • The patient's ability to reliably self-administer medication

If in doubt, it is reasonable to observe in the hospital during initial therapy and reassess early response.

Prevention

Influenza vaccine

Yearly, for everyone 6 months and older

No preference for vaccine presentation when multiple types are available within an approved age range. Some patients are revaccinated within a season if they:

  • Are immunocompromised
  • Have severe underlying COPD or heart disease
Pneumococcal vaccine

PCV13 and PPSV23

  • PCV13 — conjugate vaccine for infants, children, and adults older than 19 at high risk
  • PPSV23 — polysaccharide vaccine for adults older than 65, and those older than 2 at high risk
  • If giving both: start with PCV13, give PPSV23 at least 8 weeks later

Guidelines change frequently — check the CDC schedule.

Chapter 27

Tuberculosis

Mycobacterium tuberculosis. Rates of new infection are increasing — especially among the homeless and those in crowded conditions such as nursing homes and prisons — and the rise has coincided with more patients living with HIV and AIDS. Multidrug-resistant TB is defined as resistance to isoniazid and rifampin.

Isolation is mandatory

Patient isolation during initial evaluation and treatment, according to OSHA standards, is mandatory. This is not a judgment call.

Clinical findings

Symptoms

What the patient reports

  • Most patients are asymptomatic
  • Fever
  • Cough — generally productive of purulent sputum that may contain blood
  • Weight loss
  • Night sweats that may require changing the bed linen
Exam

What you find

  • Body temperature elevation
  • Cachexia
  • Rales over affected areas — apical posttussive rales for apical disease
Labs

What the workup shows

  • Normal CBC
  • Low serum cortisol if disseminated disease has destroyed the adrenal cortices
  • Acid-fast smears often positive — but treat empirically if findings suggest TB without a positive smear
  • Culture usually positive within 6 weeks

Chest X-ray

  • Infiltrate — especially in the upper lobes or the superior segments of the lower lobes; can appear anywhere
  • Cavity within the lungs

Reading a PPD

The test is read 48 hours after intradermal injection of 0.1 mL purified protein derivative. Measure the indurated area — the largest diameter, not including flat erythema. A positive PPD indicates exposure, not necessarily active infection.

PPD induration — the three thresholds

The cut-off that counts as "positive" drops as the patient's risk rises. Hover a bar for its value.

0 5 10 15 mm ≥ 5 mm — positive in HIV-infected patients, recent TB exposure, immunocompromised patients, or a chest film typical for TB 5 mm ≥ 5 mm ≥ 10 mm — positive in health care workers, HIV-negative injection drug users, residents of nursing homes or homeless shelters, recent immigrants 10 mm ≥ 10 mm ≥ 15 mm — positive in any person 15 mm ≥ 15 mm Anything under 5 mm is a negative test
Highest-risk patients Risk-group screening Any person
QuantiFERON TB Gold

A serum test used for diagnosis of TB — either latent or active — instead of the PPD. Its advantage: it is not affected by prior bacille Calmette-Guérin vaccination.

Treatment

Four-drug therapy is the backbone for suspected or active disease, or smear-positive disease pending culture return.

Four-drug therapy for active TB
DrugDoseWatch for
Isoniazid (INH) 300 mg PO daily — or 5 mg/kg, maximum 300 mg/day Given with pyridoxine 25–50 mg PO daily Peripheral neuropathy — prevented by pyridoxine (vitamin B6)
Rifampin Rifadin / Rimactane 600 mg PO each day — or 10 mg/kg daily, maximum 600 mg/dose —
Ethambutol Myambutol Generally 15–25 mg/kg PO daily, maximum 2.5 g/dose Precede with screening of color vision. Weight-based alternative: 40–55 kg → 800 mg; 56–75 kg → 1200 mg; 76–90 kg → 1600 mg, all PO daily. Red/green color blindness and changes in visual acuity
Pyrazinamide 15–30 mg/kg in 3 divided doses daily, maximum 2 g/dose —

Duration: usually 6–9 months — 6 months for most patients, 9 months for HIV-positive patients and pregnant women. Modify the regimen if susceptibility studies show resistance to first-line drugs.

  1. Preferred standard: INH + RIF + PZA + EMB daily for 56 doses (8 weeks), then INH + RIF for 126 doses (18 weeks).
  2. INH + RIF + PZA + EMB daily for 8 weeks, then INH + RIF 3 times weekly for 16 weeks — especially if susceptibility to INH/rifampin is noted.
  3. INH + RIF + PZA + EMB daily for 2 weeks, then the same agents 2 times weekly for 6 weeks, then INH + RIF 2 times weekly for 16 weeks — if susceptible.
  4. Thrice-weekly INH + RIF + PZA + EMB for 24 doses (8 weeks), then thrice-weekly INH + RIF for 54 doses (18 weeks).
  5. Patients with advanced HIV (CD4 < 100/mcL) should be treated with daily or three-times-weekly therapy in both the initial and continuation phases.

For nonadherent patients, directly observed treatment may be initiated at 3 times per week, usually after 2 weeks of observed therapy — often in hospital.

Consider for

  • Asymptomatic, positive PPD, normal chest X-ray
  • Exposed to active TB with a negative PPD
  • Undergoing immunosuppressive therapy for other reasons
  • HIV infected

Management

  • INH 300 mg PO daily. Controversy exists over 6 months versus up to 1 year; the standard regimen is 9 months — also the preferred duration for HIV-positive patients and pregnant women.
  • Pyridoxine 25–50 mg PO daily may be given during INH therapy to prevent neuropathy.
Chapter 27

ARDS & Acute Lung Injury

Any of the numerous causes of acute systemic inflammation can set the lung alight. The classic finding is refractory hypoxemia — and the two most common precipitants are pneumonia and sepsis.

Etiologies
Most common
Pneumonia & sepsis

The typical or usual causes of ARDS. Bacteremia and other severe systemic infections also qualify.

Massive trauma or injury

Including burns and smoke inhalation. Increased intracranial pressure — especially after trauma or intracranial bleeding — is another trigger.

Pancreatitis

Inflammation without infection can be enough to initiate the syndrome.

Shock — any cause

Cardiopulmonary bypass is a further recognised precipitant.

Aspiration

Aspiration of fluid, including gastrointestinal contents and near drowning.

The PaO₂/FiO₂ ratio — where ALI ends and ARDS begins

Two thresholds on one scale. Hover a zone for its definition.

PaO₂/FiO₂ greater than 300 — does not meet criteria for ALI or ARDS > 300 PaO₂/FiO₂ less than 300 — acute lung injury (ALI) < 300 PaO₂/FiO₂ less than 200 — ARDS < 200 No ALI / ARDS ALI ARDS 300 200 falling ratio → Lungs often sound clearer than the chest X-ray would suggest
~40%
ARDS mortality
Despite refinements in care, overall mortality remains nearly 40%.
<200
PaO₂/FiO₂ = ARDS
Below 300 is acute lung injury; below 200 is ARDS. Refractory hypoxemia is classic.
6 mL/kg
Tidal volume target
Reduced tidal volumes, typically 6 mL/kg, help prevent barotrauma.
>45 cm H₂O
Peak-pressure barotrauma risk
Persistent breath-to-breath peak pressures greater than 45 cm H₂O are a risk factor.

Clinical findings

  • Severe respiratory distress occurring during the course of one of the inciting events
  • Often requires early mechanical ventilatory assistance — refractory hypoxemia is classic
  • Symptoms: breathlessness, agitation, confusion, obtundation as oxygen delivery and uptake fall
  • Other organ failure — kidneys, liver, bone marrow (reduced platelets), multisystem organ failure
  • Lungs often sound clearer than the chest X-ray suggests
Imaging

X-ray and CT

  • Chest X-ray often shows evolving bilateral infiltrates — "whited out"
  • CT chest shows the heterogeneous nature of the opacities
Laboratory

What to order

  • ABG with PaO₂/FiO₂ ratio
  • CBC with differential and platelet count
  • Coagulation studies — PT, PTT, fibrinogen, fibrin degradation products
  • Renal and liver function · urinalysis
  • Blood and urine cultures; sputum culture and Gram stain

Treatment

First priority

Identification and prompt treatment of the underlying cause. In sepsis-associated ARDS, good outcomes require early resuscitation, appropriate antibiotics, and source control.

A — Airway

Assess and secure

  • Assess adequacy of ventilation and the work of spontaneous breathing
  • Intubate if ventilation is significantly compromised — especially with altered mentation
B — Breathing

Ventilate

  • Institute mechanical ventilation if work of breathing is not being met — patient fatigue, elevated PaCO₂
  • Or if hypoxemia is not correctable with an FiO₂ of 0.5
C — Circulation

Resuscitate

  • Vigorous fluid resuscitation if hypotension is present
  • Regulated by hemodynamic parameters, especially left ventricular ejection fraction
  • Mechanical ventilation often requires positive end-expiratory pressure (PEEP).
  • Monitor peak and plateau pressures to prevent barotrauma. Persistent breath-to-breath peak pressures greater than 45 cm H₂O are a risk factor.
  • To prevent barotrauma:
    • Reduced tidal volumes — typically 6 mL/kg
    • Pressure-cycled ventilation
    • In severe ARDS, high-frequency oscillatory ventilation may be the only way to oxygenate and ventilate
    • Permissive hypercapnia, with bicarbonate repletion to avoid excessive acidosis
  • The patient should be sedated for comfort.
  • Nutritional support started early — use the enteral route (TPN with caution if enteral is unavailable). Most patients require nearly twice their usual daily caloric requirements.
Barotrauma is the trap

The risk of pneumothorax or pneumomediastinum is high with ARDS. Sudden increases in ventilating pressure with desaturation indicate the need for an immediate repeat chest X-ray and possible chest tube insertion. Repeated physical and radiographic assessment may be needed to rule out barotrauma.

Chapter 27

The Interstitial Diseases

Two scarring diseases with one shared signature: a restrictive ventilatory defect on pulmonary function testing, a reduced diffusing capacity, and "Velcro crackles" on auscultation.

IPF

Idiopathic pulmonary fibrosis

Etiology unknown; strongly linked to cigarette smoking. The most common cause of interstitial lung disease among elderly patients, and more common in men.

Symptoms: progressive dyspnea (slow or rapid) and nonproductive cough.

Sarcoidosis

Noncaseating granulomas

Characterised pathologically by noncaseating granulomas and interstitial lung disease, with systemic manifestations: lymphadenopathy, cardiac involvement, iritis, cutaneous lesions, arthritis, GI involvement.

More common among females, North Americans, African Americans, and northern European Caucasians. Typical onset ages 20–40.

Before you treat either one — rule these out
  • Inhalation exposure — inorganic dusts (silica, asbestos), organic dusts (silos — hypersensitivity pneumonia), fumes (chlorine, sulfur dioxide)
  • Drugs — chemotherapeutic agents (bleomycin), antibiotics (nitrofurantoin, sulfa), gold salts, amiodarone
  • Autoimmune disorders
  • Chronic lung infection — tuberculosis, deep fungal infection (histoplasmosis, coccidioidomycosis)
  • Radiation to lung parenchyma
  • In patients with prior malignancy — exclude lymphangitic spread of tumor

Sarcoidosis staging

The five stages on chest X-ray

Used to stage pulmonary involvement. Hover each stage.

Stage 0 — normal chest X-ray Stage 0 normal Stage I — bilateral hilar lymphadenopathy (BHL) Stage I BHL Stage II — BHL plus pulmonary infiltrates Stage II BHL + infiltrates Stage III — pulmonary infiltrates without BHL Stage III infiltrates, no BHL Stage IV — pulmonary fibrosis Stage IV fibrosis Increasing pulmonary involvement →
Diagnostics

Shared findings

  • CXR and high-resolution CT — interstitial infiltrates, nodules, cystic ("honeycombing") changes, especially in the lower lobes
  • PFTs — restrictive ventilatory defect; DLCO commonly reduced
  • ABG and pulse oximetry — hypoxemia as disease progresses; CO₂ retention indicates severe disease
  • Tissue: fiber-optic bronchoscopy with transbronchial biopsy first; bronchoalveolar lavage at the same time; thoracoscopic lung biopsy if more assurance is needed
Also check

Don't miss these

  • PPD testing should be done in both
  • Complement fixation serology for deep fungi — histoplasmosis, coccidioidomycosis, blastomycosis
  • Sarcoidosis is associated with hypercalcemia — check calcium
  • Sarcoidosis blood panel: CBC, calcium, LFTs, BUN, creatinine; plus EKG, urinalysis, PPD, ophthalmologic exam
  • Vaccinate IPF patients against influenza and pneumococcus — these infections are poorly tolerated

Treatment

IPF — no cure

  • No procedure or medication can remove the scarring
  • Pirfenidone (Esbriet) and nintedanib (Ofev) slow progression
  • Oxygen support to maximise blood oxygen levels
  • Lung rehabilitation — helps exercise with less dyspnea
  • Noninvasive positive airway pressure by mask may benefit selected patients
  • Lung transplant for advanced disease
  • Prognosis is often poor; counsel on palliative care and end-of-life issues

Sarcoidosis — individualized

  • No cure; treatment based on symptoms and severity of organ involvement
  • Refer to specialists for the organs involved
  • Alternatives are indicated only when sarcoidosis does not respond to oral corticosteroids, when there is intolerance or contraindication, or when the steroid dose must be reduced
  • Options: methotrexate, hydroxychloroquine, azathioprine, cyclophosphamide, infliximab, adalimumab, leflunomide
Chapter 27

CHF & Cardiogenic Pulmonary Edema

The heart fails, the lung floods. Clinical manifestations come from restrictive ventilatory defects within the lung parenchyma that begin mild and later become severe.

Etiology

Most common driver

Ischemia

Coronary artery disease with myocardial ischemia and infarction — aggravated by obesity, limited exercise, dyslipidemia, and cigarette smoking.

Rhythm & pressure

  • Arrhythmias — tachycardia especially, and bradycardia
  • Hypertension
  • Valvular dysfunction

Everything else

  • Thyroid dysfunction — hyper- or hypothyroidism
  • Diabetes mellitus
  • Viral myocarditis
  • Idiopathic cardiomyopathy
  • Renal failure
  • Drug therapy — especially certain chemotherapeutic agents

Symptoms & the NYHA scale

Watch the progression: exertional dyspnea → orthopnea → paroxysmal nocturnal dyspnea. Frank respiratory failure may follow. A dry cough is common. The time course may be slow or abrupt.

NYHA functional classification

The higher the class, the less the patient can do. Hover a bar.

NYHA 1 — no limitations from ordinary activities No limitation NYHA 2 — slight limitations with moderate exertion Slight NYHA 3 — marked limitation with activity; comfortable only at rest Marked NYHA 4 — symptoms with any activity and occasionally at rest; the patient should be on complete rest Symptoms at rest NYHA 1 NYHA 2 NYHA 3 NYHA 4
Physical exam

Signs of fluid retention

  • Edema and jugular venous distention
  • Rales
  • Tachycardia or bradycardia
  • Inability to tolerate lying flat — orthopnea
  • Tachypnea
  • Pleural effusions
  • Ascites when CHF is advanced
Chest X-ray

What to look for

  • Vascular redistribution to upper lung fields
  • Interstitial edema
  • Kerley B lines
  • Pleural effusions — usually bilateral or on the right
  • Cardiomegaly
  • EKG — assess for ischemia or infarction; determine rhythm
  • Oxygenation — ABG and pulse oximetry, to ensure adequate oxygenation and assess CO₂ retention
  • CBC — to rule out anemia
  • Chemistries — TSH (if abnormal, check free T3/T4 to separate true disease from euthyroid sick state), renal function (BUN, creatinine), liver function, electrolytes including magnesium
  • Cardiac enzymes — especially if recent MI or unstable angina is suspected
  • Echocardiography — systolic function (rate of demise matters more than the actual ejection fraction), valvular function, global and segmental dyskinesia, diastology, right heart pressures to detect pulmonary hypertension
  • Pulmonary function studies — not useful during acute pulmonary edema, but when stable they can demonstrate a restrictive defect (reduced vital capacity) and evaluate coexisting COPD
  • Pulmonary artery catheterization — occasionally needed to document severity, especially with hypotension. In general, insertion is not necessary in treating CHF.
The PA catheter caveat

When hypotension is present, aggressive fluid therapy could further aggravate CHF. Catheterization can determine cardiac output, cardiac index, systemic vascular resistance, and pulmonary capillary wedge pressure — but it is not routine.

Treatment

Correct the cause of the CHF if known, especially ischemia. Guide fluid administration with bedside ultrasound measurement of the inferior vena cava (IVC) or EKG, along with clinical indicators of volume status. Nitrates may be indicated — but may or may not be appropriate depending on the cause (e.g., arrhythmia, valvular heart disease).

  • Sublingual or intravenous nitroglycerin
  • Nitroglycerin patches such as Nitro-Dur 0.4 mg, applied daily
  • Oral, long-acting nitrates such as isosorbide
  • Supplement oxygen, usually via nasal cannula at low flow rates (e.g., 2 L/min).
  • In frank pulmonary edema, oxygen should be supplied in higher amounts — use mask delivery PRN.
  • If the patient cannot sustain the work of breathing during an acute episode, attempt noninvasive positive pressure ventilation via CPAP, followed by intubation and mechanical ventilation if necessary. This redistributes edema out of the lungs and back into the vascular space, and offloads the work of breathing.
  • Eliminate cardiac depressants. Nondihydropyridine calcium channel blockers (diltiazem, verapamil). Remove β-blockers for acute decompensation and resume when clinically stable.
  • Inotropic support in acute decompensation — dobutamine and milrinone.
    Note: inotropes should only be started when there is hypotension and evidence of reduced organ perfusion. In these cases dobutamine is usually first-line.
  • Decrease afterload with an ACE inhibitor or angiotensin II receptor blocker (ARB) as blood pressure tolerates.
  • Decrease preload with appropriate diuretics. If the patient has chest pain, morphine may be used as well.
  • β-adrenergic antagonists to help regulate catecholamines — if blood pressure and heart rate will tolerate.
  • Together these reduce interstitial edema and ventilatory restriction, improving respiratory symptoms. Aggressiveness must be proportionate to the severity of interstitial edema and respiratory distress.
For Study

What to lock in

If this week supports one study habit, it is to keep the four jobs of gas exchange and the two defect classes straight, and to anchor every threshold to the number that triggers action. These are the high-yield contrasts to carry forward.

Distinguish

Oxygenation vs. ventilation

Oxygenation = getting O₂ into blood (track PaO₂/SaO₂). Ventilation = moving CO₂ out (track PaCO₂). A patient can be well ventilated and still hypoxemic — and vice versa.

Distinguish

Obstructive vs. restrictive

Obstructive = flow ↓ (FEV₁/FVC < 70%), volumes normal/↑. Restrictive = flow normal/↑, volumes ↓ (TLC ↓). One ratio separates them.

Sequence

ABG interpretation

pH → PaCO₂ → HCO₃ → the 0.08 rule → PaO₂/FiO₂. Every 10 mmHg of PaCO₂ moves pH 0.08 the other way; any leftover is metabolic.

Sequence

Reading a CXR

Patient → orientation/rotation → penetration → inspiration → ABCDEHI — then compare to priors. Same order, every film, no exceptions.

Recognize

Type 1 vs. Type 2 failure

Type 1 = PaO₂ < 60 (hypoxemia). Type 2 = PCO₂ > 50 (hypercapnia) in the absence of chronic retention. Type 3 is atelectasis from low FRC; Type 4 is underperfused respiratory muscles.

Recognize

The barotrauma threshold

Peak pressure > 45 cm H₂O is the barotrauma risk; keep plateau ≤ 30 cm H₂O with tidal volumes of 6–8 mL/kg IBW.

Remember

The oximeter lies about content

It reads saturation, not content. Anemia + 100% SpO₂ can still be under-oxygenated — and CO gives a falsely high reading. "100% of half is still half."

Remember

Chronic CO₂ retainers

They breathe on their hypoxemic drive. Give O₂ at low flow (1–2 L/min) and watch for apnea — but never withhold needed oxygen.

Remember

Weaning gate

FiO₂ ≤ 0.40 and PEEP ≤ 8, SBP ≥ 90 without pressors, no blockade → daily spontaneous breathing trial of 30–120 minutes.

The one-sentence version of Week 4

Perfuse it, ventilate it, and let it diffuse — measure all three, image and test what fails, ventilate what collapses, and keep the airway open when the lungs forget how.

Self-Check

Rapid-fire review

Answer out loud first, then reveal. Sixteen questions covering all seven chapters.

State the normal ABG values — pH, PaO₂, PaCO₂, HCO₃, base excess, and SaO₂.

pH 7.35–7.45 · PaO₂ 80–97 mmHg · PaCO₂ 35–45 mmHg · HCO₃ 22–26 mEq/L · base excess −3 to +3 mEq/L · SaO₂ > 98%.

A patient's PaCO₂ is rising. What does that tell you about ventilation?

Ventilation is reciprocally reflected by PaCO₂ — a rising PaCO₂ means ventilation has decreased. PaCO₂ is the best indicator of alveolar ventilation.

Using the 0.08 rule, what pH does a PaCO₂ of 50 predict?

7.32. Every 10 mmHg shift in PaCO₂ produces a reciprocal 0.08 shift in pH (40 → 50 is +10 mmHg, so 7.40 − 0.08 = 7.32). Any difference from that predicted shift is a concurrent metabolic imbalance or compensation.

What PaO₂ does an SpO₂ of 90% represent? 75%? 50%?

SpO₂ 90% → PaO₂ 60 mmHg · 75% → 40 mmHg · 50% → 27 mmHg. The relationship is nonlinear.

Name two causes of a left shift and two of a right shift of the oxyhemoglobin dissociation curve.

Left shift (↑ affinity): alkalosis, hypothermia, decreased 2,3-DPG. Right shift (↓ affinity): acidosis, hyperthermia/increased metabolism/anaerobic metabolism, increased 2,3-DPG.

What is the normal SvO₂, and what does a value below 60% mean?

Normal SvO₂ is 75% (acceptable 60–80%). Below 60% (or trending down) means the patient has tapped the venous oxygen reserve and is at greater risk of anaerobic metabolism — from decreased O₂ supply or increased demand.

What are the normal A-a gradient values on room air and on 100% oxygen?

Young adult on room air: < 10 mmHg. Over age 60 on room air: < 20 mmHg. On FiO₂ 100%: < 50 mmHg.

What is the normal PaO₂/FiO₂ ratio, and what ratio marks severe hypoxemia?

Normal is 300–500. Low ratios indicate impaired O₂ exchange; a ratio below 200 mmHg indicates severe hypoxemia.

How does the PA catheter distinguish cardiogenic from pulmogenic pulmonary edema?

Cardiogenic edema: high PCWP, normal PAP. Pulmogenic edema: normal PCWP, high PAP.

Of 1 L of normal saline infused, how much stays intravascular?

Only about 250 mL — the rest moves to the interstitial space. High-volume normal saline resuscitation is also associated with hyperchloremic acidosis.

Where should an endotracheal tube tip sit on chest X-ray? A PA catheter? An NG tube?

ETT: 3–7 cm above the carina (or T5–T7). PA catheter: in the (usually right) pulmonary artery, 2–4 cm from midline. NG tube: below the diaphragm, tip and side holes 10 cm into the gastric antrum.

What are Kerley B lines, and what disease do they suggest?

Horizontal lines less than 2 cm long near the costophrenic angle — a sign of cardiogenic pulmonary edema / heart failure (along with cephalization and alveolar edema).

Who qualifies for yearly low-dose CT lung cancer screening, and what is its mortality benefit?

Aged 55–80 years, current smoker or quit within the past 15 years, with a 30 pack-year history. Low-dose CT screening decreases mortality by 20%.

What FEV₁/FVC ratio defines airflow obstruction, and what counts as a positive bronchodilator response?

FEV₁/FVC < 70% (adults) = obstruction. A positive bronchodilator response is an increase of 12% or 200 mL or more in FEV₁.

What are the three peak-flow zones and their cut-offs?

Green 80–100% of baseline (no change) · Yellow 50–80% (intensify therapy) · Red below 50% (urgent/emergency care). Peak flow meters monitor asthma — they don't diagnose it.

A COPD patient is intubated. What tidal volume target and plateau pressure do you aim for?

Tidal volume 6–8 mL/kg ideal body weight, keeping plateau pressure ≤ 30 cm H₂O to prevent barotrauma. Persistent peak pressures > 45 cm H₂O are the barotrauma risk factor.

State the daily spontaneous-breathing-trial gate and the trial duration.

Gate: FiO₂ ≤ 0.40 and PEEP ≤ 8, PEEP/FiO₂ ≤ the prior day, acceptable spontaneous effort, SBP ≥ 90 mmHg without vasopressors, no NM blockade. Trial: 30–120 minutes; if tolerated, the patient usually tolerates extubation.

Differentiate Type 1 from Type 2 respiratory failure.

Type 1 = hypoxemia, PaO₂ < 60 mmHg (diffusion defects, V/Q mismatch, shunt, altitude). Type 2 = hypercapnia, PCO₂ > 50 mmHg in the absence of chronic retention (alveolar hypoventilation).

What GOLD FEV₁ values define mild, moderate, severe, and very severe COPD?

GOLD 1 (mild): FEV₁ ≥ 80%. GOLD 2 (moderate): 50–80%. GOLD 3 (severe): 30–50%. GOLD 4 (very severe): < 30% of predicted.

What oxygenation targets imply adequacy in COPD, and what hematocrit suggests secondary polycythemia?

Adequate oxygenation when SaO₂ > 88% and hemoglobin > 10 g/dL. A hematocrit > 55% indicates secondary polycythemia from chronic hypoxemia.

How should asthma–COPD overlap syndrome (ACOS) be treated?

There are no standardized criteria or pathway — GINA and GOLD recommend treating according to the dominant phenotype. Over 40% of COPD patients self-report asthma, and dual diagnosis progresses more rapidly.

What defines "copious" sputum in bronchiectasis, and what is a key diagnostic and treatment point?

One or more cups of sputum per day, occasionally bloody. Diagnosis: CT documents airway dilatation and bronchial wall thickening. Treatment emphasizes percussive therapy + postural drainage, mucolytics, and antibiotics (even prophylactically).

References

Sources

Every statement above comes from the assigned Week 4 reading — seven chapters of Practice Considerations for Adult-Gerontology Acute Care Nurse Practitioners.

Chapters

Avadhani, A. (2021). Diagnostic concepts of oxygenation and ventilation. In Practice considerations for adult-gerontology acute care nurse practitioners (3rd ed., Chapter 22).

Akintade, B. (2021). Measures of oxygenation and ventilation. In Practice considerations for adult-gerontology acute care nurse practitioners (3rd ed., Chapter 23).

Ku, V. F. (2021). The chest X-ray. In Practice considerations for adult-gerontology acute care nurse practitioners (3rd ed., Chapter 24).

Hoy, H. M. (2021). Pulmonary function testing. In Practice considerations for adult-gerontology acute care nurse practitioners (3rd ed., Chapter 25).

Avadhani, A. (2021). Mechanical ventilatory support. In Practice considerations for adult-gerontology acute care nurse practitioners (3rd ed., Chapter 35).

Harse, A. (2021). Respiratory failure. In Practice considerations for adult-gerontology acute care nurse practitioners (3rd ed., Chapter 30).

Inocencio, B. (2021). Obstructive (ventilatory) lung diseases. In Practice considerations for adult-gerontology acute care nurse practitioners (3rd ed., Chapter 26).

Week 4 · Pulmonary Disorders I — built locally from N5301 Week 04 - Sep 14 - Pulmonary Disorders I.pdf. This report is a single self-contained HTML file: fully offline, no login, no external dependencies. Press Cmd+P to print a copy with every section expanded.